A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients

Conclusion: The outcome of alloSCT after relapse is not inferior to that of alloSCT in CR1, supporting the role of alloSCT after relapse in the setting of limited donors and resources.

Source: In Vivo - January 5, 2021 Category: Research Authors: OH, M. J., SHIN, D.-Y., KOH, Y., HONG, J., KIM, I., YOON, S.-S., BYUN, J. M. Tags: Clinical Studies Source Type: research